NCT00822185 - Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Congenital Bleeding DisorderHealthy

Interventions

DRUG

vatreptacog alfa (activated)

One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg

DRUG

vatreptacog alfa (activated)

One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg

DRUG

vatreptacog alfa (activated)

One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg

DRUG

vatreptacog alfa (activated)

One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg

DRUG

placebo

Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg

DRUG

placebo

Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg

DRUG

placebo

Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg

DRUG

placebo

Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg

Trial Locations (1)

Tokyo